Discover
IBRX
ImmunityBio, Inc.
9.20
2 x 6.64
56 x 39.90
bid
ask
+
0.44
5.08%
29 @ 05:39 AM
9.12 -0.08 (0.87%)
| Ytd | 364.65% | |
| 1y | 257.98% |
8.51
day range
9.34
1.95
52 week range
12.43
| Open | 8.64 | Prev Close | 8.76 | Low | 8.51 | High | 9.34 | Mkt Cap | 9.64B |
| Vol | 16.29M | Avg Vol | 13.96M | EPS | -0.85 | P/E | N/A | Forward P/E | 145.92 |
| Beta | 0.10 | Short Ratio | 9.65 | Inst. Own | 17.60% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 7.65 | 200-d Avg | 5.36 | 1yr Est | 13.00 |
| Income Statement | |||
| Total Revenue | 44.21M | ||
| Revenues (USD) | 44.21M | ||
| Cost of Revenue | 238.00K | ||
| Gross Profit | 43.97M | ||
| Operating Expenses | 113.76M | ||
| Research and Development Expense | 67.99M | ||
| Selling, General and Administrative Expense | 45.77M | ||
| Operating Income | -69.79M | ||
| Interest Expense | 28.46M | ||
| Income Tax Expense | 9.00K | ||
| Net Income | -632.78M | ||
| Net Income Common Stock | -632.78M | ||
| Net Income Common Stock (USD) | -632.78M | ||
| Consolidated Income | -632.80M | ||
| Net Income to Non-Controlling Interests | -15.00K | ||
| Earnings per Basic Share | -0.62 | ||
| Earnings per Basic Share (USD) | -0.62 | ||
| Earnings per Diluted Share | -0.62 | ||
| Earning Before Interest & Taxes (EBIT) | -604.31M | ||
| Earning Before Interest & Taxes (USD) | -604.31M | ||
| Weighted Average Shares | 1.03B | ||
| Weighted Average Shares Diluted | 1.03B | ||
| Balance Sheet | |||
| Cash and Equivalents | 205.19M | ||
| Cash and Equivalents (USD) | 205.19M | ||
| Investments | 175.69M | ||
| Investments Current | 175.69M | ||
| Trade and Non-Trade Receivables | 43.27M | ||
| Current Assets | 452.95M | ||
| Property, Plant & Equipment Net | 145.82M | ||
| Total Assets | 646.64M | ||
| Debt Current | 7.63M | ||
| Total Debt | 1.12B | ||
| Current Liabilities | 67.95M | ||
| Debt Non-Current | 1.12B | ||
| Total Liabilities | 1.52B | ||
| Accumulated Retained Earnings (Deficit) | -4.36B | ||
| Accumulated Other Comprehensive Income | 27.45M | ||
| Shareholders Equity | -870.01M | ||
| Shareholders Equity (USD) | -870.01M | ||
| Assets Non-Current | 193.68M | ||
| Total Debt (USD) | 1.12B | ||
| Goodwill and Intangible Assets | 12.89M | ||
| Inventory | 19.40M | ||
| Liabilities Non-Current | 1.45B | ||
| Trade and Non-Trade Payables | 12.12M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 6.08M | ||
| Net Cash Flow from Financing | 223.93M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 117.04M | ||
| Capital Expenditure | -1.79M | ||
| Issuance (Purchase) of Equity Shares | 149.75M | ||
| Issuance (Repayment) of Debt Securities | -820.00K | ||
| Net Cash Flow from Investing | -31.65M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -29.86M | ||
| Net Cash Flow from Operations | -75.36M | ||
| Effect of Exchange Rate Changes on Cash | 122.00K | ||
| Share Based Compensation | 8.17M | ||